Benign Prostatic Hyperplasia - Is Apitherapy a Reasonable Therapeutic Option?

Benign Prostatic Hyperplasia - Is Apitherapy a Reasonable Therapeutic Option?

Identification: unj_so20_02
Issue: September-October 2020
Volume: Volume 40 Number 5
Credits (Post Test and/or Evaluation Required)
Available until 10/31/2022
  • 1.30 - CH


Contact hours available until 10/31/22.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Faculty, Planners and Authors Conflict of Interest Disclosure:
The author(s), editor, editorial board, content reviewers, and education director reported no actual or potential conflict of interest in relation to this continuing nursing education article.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
This educational activity is provided by the Society of Urologic Nurses and Associates (SUNA).

The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. 

SUNA is a provider approved by the California Board of Registered Nursing, Provider Number CEP 5556. 

This article was reviewed and formatted for contact hour credit by Michele Boyd, MSN, RN, NPD-BC, SUNA Education Director.

Learning Outcome: 
After completing this education activity, the learner will be able to discuss the recommendations of apitherapists regarding the use of bee products for benign prostate hyperplasia (BPH) and compare these recommendations with current scientific evidence.

Credits Available

Expired On: Oct 31, 2022

You must be logged in and own this product in order to post comments.